Zotarolimus

Drug Profile

Zotarolimus

Alternative Names: ABT 578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Onyx; ZoMaxx; Zotarolimus-eluting coronary stent system

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Medtronic
  • Class Ischaemic heart disorder therapies; Lactones; Macrolides; Polyenes; Tetrazoles
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Erectile dysfunction
  • Discontinued Vascular restenosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Erectile-dysfunction in USA (Intra-arterial, Implant)
  • 31 May 2016 Medtronic completes the RESOLUTE US trial for Coronary artery restenosis (NCT00726453)
  • 01 Dec 2015 Medtronic completes a phase III trial in Coronary artery restenosis in China (Intracoronary) (NCT02452736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top